Dopamine- and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-DOPA)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors

Biochemical Pharmacology

Volumn 53, Issue 3, 1997, Pages 363-372

  Lai, Chien Tsai ^a,b   Yu, Peter H ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

antioxidants; cytotoxicity; dopamine; L DOPA; oxidative stress; SH SY5Y cells

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CATALASE; CHELATING AGENT; DEFEROXAMINE; DOPAMINE; GLUTATHIONE; HYDROGEN PEROXIDE; LEVODOPA; MANNITOL; N TERT BUTYL ALPHA PHENYLNITRONE; REACTIVE OXYGEN METABOLITE; SALICYLIC ACID; SCAVENGER; SUPEROXIDE DISMUTASE;

ARTICLE; CATECHOLAMINE NERVE CELL; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; LIPID PEROXIDATION; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NEUROBLASTOMA CELL; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0031042677     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00731-9     Document Type: Article

References (66)

1. Ambani LM, Van Woert MH and Murphy S, Brain peroxidase and catalase in Parkinson's disease. Arch Neurol 32: 114-116, 1975.
2. Kish SJ, Morito C and Hornykiewicz O, Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 58: 343-346, 1985.
3. Götz ME, Freyberger A and Riederer P, Oxidative stress: A role in the pathogenesis of Parkinson's disease. J Neurol Transm Suppl 29: 241-249, 1990.
4. Perry TL, Godin DV and Hansen S, Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305-310, 1982.
5. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K and Youdim MBH, Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520, 1989.
6. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P and Marsden CD, Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 348-355, 1994.
7. Marttila RJ, Lorentz H and Rinne UK, Oxygen toxicity protecting enzymes in Parkinson's disease: Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86: 321-331, 1988.
8. Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P and Marsden CD, A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53: 692-697, 1989.
9. Dexter DR, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P and Marsden CD, Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830-1836, 1989.
10. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F and Agid Y, Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: An X-ray microanalysis. J Neurochem 56: 446-451, 1991.
11. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P and Youdim MBH, Brain iron and ferritin in Parkinson's and Alzheimer's disease. J Neurol Transm [P-D Sect] 2: 327-340, 1990.
12. Sofic E, Paulus W, Jellinger K, Riederer P and Youdim MBH, Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56: 978-982, 1991.
13. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P and Marsden CD, Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389, 1989.
14. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P and Marsden CD, Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study. Mov Disord 9: 92-97, 1994.
15. Sanchez-Ramos JR, Overvik E and Ames BN, A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3: 197-204, 1994.
16. Agid Y, Javoy-Agid F and Ruberg M, Biochemistry of neurotransmitters in Parkinson's disease. In: Movement Disorders 2 (Eds. Marsden CD and Fahn S), pp. 166-230. Butterworth-Heinemann, London, 1987.
17. Agid Y, Ruberg M, Raisman R, Hirsch E and Javoy-Agid F, The biochemistry of Parkinson's disease. In: Parkinson's disease (Ed. Stern GM), pp. 99-125. Johns Hopkins University Press, Baltimore, 1990.
18. Hornykiewicz O and Kish SJ, Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45: 19-34, 1986.
19. Scatton B, Javoy-Agid F, Montfort JC and Agid Y, Neurochemistry of monoaminergic neurons in Parkinson's disease. In: Catecholamines: Neuropharmacology and Central Nervous System-Therapeutic Aspects (Eds. Usdin E, Carlsson A, Dahlstrom A and Engel J), pp. 43-52. Alan R. Liss, New York, 1984.
20. Fornstedt B, Pileblad E and Carlsson A, In vivo autoxidation of dopamine in guinea pig striatum increases with age. J Neurochem 55: 655-659, 1990.
21. Fornstedt B and Carlsson A, Effects of inhibition of monoamine oxidase on the levels of 5-cysteinyl adducts of catechols in dopaminergic regions of the brain of the guinea pig. Neuropharmacology 30: 463-468, 1991.
22. Graham DG, Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 24: 633-643, 1978.
23. Chiueh CC, Miyake H and Peng M, Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol 60: 251-258, 1993.
24. Cohen G, The pathobiology of Parkinson's disease: Biochemical aspects of dopamine neuron senescence. J Neural Transm Suppl 19: 89-103, 1983.
25. Cohen G, Monoamine oxidase and oxidative stress at dopaminergic synapses. J Neural Transm Suppl 32: 229-238, 1990.
26. Filloux F and Townsend JJ, Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 119: 79-88, 1993.
27. Spina MB and Cohen G, Dopamine turnover and glutathione oxidation: Implications for Parkinson's disease. Proc Natl Acad Sci USA 86: 1398-1400, 1989.
28. Rosenberg PA, Catecholamine toxicity in cerebral cortex in dissociated cell culture. J Neurosci 8: 2887-2894, 1988.
29. Michel PP and Hefti F, Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26: 428-435, 1990.
30. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP and Barrett RE, Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253-1261, 1979.
31. Yahr MD, Long-term levodopa in Parkinson's disease. Lancet i: 706-707, 1977.
32. Ogawa N, Edamatsu R, Mizukawa K, Asanuma M, Kohno M and Mori A, Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv Neurol 60: 242-250, 1993.
33. Zigmond MJ, Hastings TG and Abercrombie ED, Neurochemical responses to 6-hydroxydopamine and L-DOPA therapy: Implications for Parkinson's disease. Ann NY Acad Sci 648: 71-86, 1992.
34. Graham DG, Tiffany SM, Bell WR and Gutknecht WF, Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644-653, 1978.
35. Graham DG, Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 5: 83-96, 1984.
36. Spina MB, Squinto SP, Miller J, Lindsay RM and Hyman C, Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenyl-pyridinium ion toxicity: Involvement of the glutathione system. J Neurochem 59: 99-106, 1992.
37. Sato K, Saito H and Katsuki H, Synergism of tocopherol and ascorbate on the survival of cultured brain neurons. Neuroreport 4: 1179-1182, 1993.
38. Branch DR and Guilbert LJ, Practical in vitro assay systems for the measurement of hematopoietic growth factors. J Tissue Cult Methods 10: 101-108, 1986.
39. Mosmann T, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
40. Ohkawa H, Ohishi N and Yagi K, Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95: 351-358, 1979.
41. Esterbauer H, Lang J, Zadravec S and Slater TF, Detection of malonaldehyde by high-performance liquid chromatography. Methods Enzymol 105: 319-328, 1984.
42. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
43. d'Ischia M, Costantini C and Prota G, Reaction of dopamine with malondialdehyde: A possible underlying event in Parkinson's disease. Tetrahedron Lett 34: 3921-3924, 1993.
44. McCay PB, Vitamin E: Interactions with free radicals and ascorbate. Annu Rev Nutr 5; 323-340, 1985.
45. Niki E, Interaction of ascorbate and α-tocopherol. Ann NY Acad Sci 498: 186-199, 1987.
46. Packer JE, Slater TF and Willson RL, Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 278: 737-738, 1979.
47. Andén N, Fuxe K, Hamgerger B and Hökfelt T, A quantitative study on the nigro-neostriatal dopamine neuron system in the rat. Acta Physiol Scand 67: 306-312, 1966.
48. Cohen G, Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv Neurol 45: 119-125, 1986.
49. Blunt SB, Jenner P and Marsden CD, Suppressive effect of L-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 8: 129-133, 1993.
50. Fuller RW, Comparison of MPTP and amphetamines as dopaminergic neurotoxins. Ann NY Acad Sci 684: 87-95, 1992.
51. Panfili E, Sandri G and Ernster L, Distribution of glutathione peroxidases and glutathione reductase in rat brain mitochondria. FEBS Lett 290: 35-37, 1991.
52. Peeters-Joris C, Vandevoorde A and Baudhuin P, Subcellular localization of superoxide dismutase in rat liver. Biochem J 150: 31-39, 1975.
53. Weisiger RA and Fridovich I, Mitochondrial superoxide dismutase. Site of synthesis and intramitochondrial localization. J Biol Chem 248: 4793-4796, 1973.
54. Borg DC and Schaich KM, Pro-oxidant action of antioxidants. In: CRC Handbook of Free Radicals and Antioxidants in Biomembrane (Eds. Miquel J, Quintanilha AT and Weber H), Vol. 1, pp. 63-80. CRC Press, Boca Raton, 1989.
55. Roginsky VA and Stegmann HB, Ascorbyl radical as natural indicator of oxidative stress: Quantitative regularities. Free Radiac Biol Med 17: 93-103, 1994.
56. Hemila H, Roberts P and Wikstrom M, Activated polymorphonuclear leucocytes consume vitamin C. FEBS Lett 178: 25-30, 1984.
57. Nichikimi M, Oxidation of ascorbic acid with superoxide anion generated by the xanthine-xanthine oxidase system. Biochem Biophys Res Commun 63: 463-468, 1975.
58. Rose RC, Ascorbic acid protection against free radicals. Ann NY Acad Sci 498: 506-508, 1987.
59. Ciuffi M, Gentilini G, Franchi-Micheli S and Zilletti L, Lipid peroxidation induced "in vivo" by iron-carbohydrate complex in the rat brain cortex. Neurochem Res 16: 43-49, 1991.
60. Zaleska MM, Nagy K and Floyd RA, Iron-induced lipid peroxidation and inhibition of dopamine synthesis in striatum synaptosomes. Neurochem Res 14: 597-605, 1989.
61. Burton GW and Ingold KU, Vitamin E as an in vitro and in vivo antioxidant. Ann NY Acad Sci 570: 7-22, 1989.
62. Van Acker SABE, Koymans LMH and Bast A, Molecular pharmacology of vitamin E: Structural aspects of antioxidant activity. Free Radic Biol Med 15: 311-328, 1993.
63. The Parkinson Study Group, Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183, 1993.
64. Shinar E, Navok T and Chevion M, The analogous mechanisms of enzymatic inactivation induced by ascorbate and superoxide in the presence of copper. J Biol Chem 258: 14778-14783, 1983.
65. Pryor WA, Oxy-radicals and related species: Their formation, lifetimes, and reactions. Annu Rev Physiol 48: 657-667, 1986.
66. Sies H, Oxidative stress: From basic research to clinical application. Am J Med 91 Suppl 3C: 31S-38S, 1991.